Drug Search Results
More Filters [+]

KW-2450

Alternative Names: kw-2450, kw2450, kw 2450
Latest Update: 2024-04-25
Latest Update Note: Clinical Trial Update

Product Description

KW-2450 is an oral dual insulin-like growth factor-1 receptor/insulin receptor tyrosine kinase inhibitor.

Mechanisms of Action: IGF Inhibitor,INSR Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Kyowa Hakko Kirin
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for KW-2450

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Breast Cancer|Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2450-US-002

P1

Terminated

Breast Cancer

2012-12-01

39%

2450-US-001

P1

Completed

Oncology Solid Tumor Unspecified

2010-08-01

39%

Recent News Events

Date

Type

Title